Glycoconjugates

Name
Glycoconjugates
Accession Number
DBCAT000084
Description

Carbohydrates covalently linked to a nonsugar moiety (lipids or proteins). The major glycoconjugates are glycoproteins, glycopeptides, peptidoglycans, glycolipids, and lipopolysaccharides. (From Biochemical Nomenclature and Related Documents, 2d ed; From Principles of Biochemistry, 2d ed)

Drugs
DrugDrug Description
PegfilgrastimA recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy.
FilgrastimA form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
OritavancinAn antibacterial agent used to treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.
Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
BleomycinA chemotherapy agent used to treat various malignancies, including head and neck malignancy, lymphoma, and testicular tumors, among others.
VancomycinA glycopeptide antibiotic used to treat severe but susceptible bacterial infections such as MRSA (methicillin-resistant Staphylococcus aureus) infections.
TU-514Not Available
PhosphoramidonNot Available
BalhimycinBalhimycin is a novel glycopeptide antibiotic.
SulfatideAny of a class of cerebroside sulfuric esters, they are found largely in the medullated nerve fibers and may accumulate in metachromatic leukodystrophy.
LJP 1082Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
CefilavancinInvestigated for use/treatment in bacterial infection, skin infections/disorders, and staph bacterial infections.
TeicoplaninA glycopeptide antibiotic with a similar mechanism of action and spectrum of activity to vancomycin used to treat various infections caused by gram-positive bacteria.
DalbavancinAn antibacterial used to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of Gram-positive bacteria.
TelavancinAn antibacterial agent used in the treatment of complicated skin and skin structure infections and types of hospital-acquired bacterial pneumonia.
UlinastatinUlinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.
KRN-7000KRN7000 has been used in trials studying the treatment of Lung Cancer, Chronic Hepatitis C, Hepatitis B, Chronic, Unspecified Adult Solid Tumor, Protocol Specific, and Prevention of GvHD in Patients...
SiagosideSiagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a...
RivipanselRivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal impairment, Anemia, Sickle Cell, Sickle Cell Disease, and Sickle Cell Disorders, among others.
Bleomycin A6Bleomycin A6 (also known as boanmycin) has been used in trials studying the treatment of Squamous Cell Lung Cancer. It was developed in China as an antineoplastic antibiotic. This drug...
Ceramide NPCeramide NP is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin. Ceramide 3...
Ceramide APNot Annotated
Ceramide NGNot Annotated
UproleselanUproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).
ImgatuzumabImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With...
NaxitamabA GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
ABX-196ABX-196 is under investigation in clinical trial NCT03897543 (ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma).
Simoctocog alfaAn antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency).
Darbepoetin alfaA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
ErythropoietinA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
SargramostimA modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant.
Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
Alpha-1-proteinase inhibitorA purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
ThyroglobulinFor the treatment of hypothyroidism (deficiency in the production of thyroid hormone).
AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
RomiplostimA fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
RegramostimInvestigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
Talactoferrin alfaInvestigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
TG4010Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
Methoxy polyethylene glycol-epoetin betaA synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease.
Conestat alfaA recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.
Gastric intrinsic factorIntrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic...
Epoetin deltaEpoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
MuplestimMuplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in...
MolgramostimMolgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.
TecemotideTecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
BalugrastimBalugrastim has been used in trials studying the treatment of Solid Tumors.
LenograstimA granulocyte colony-stimulating factor indicated in the reduction of duration of neutropenia in bone marrow transplant and cytotoxic chemotherapy, as well as mobilizing hematopoietic stem cells in healthy donors.
Protein S humanA medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy.
LipegfilgrastimA medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy.
SulglicotideNot Annotated
Zinpentraxin alfaZinpentraxin alfa is a recombinant form of PTX-2, a naturally circulating human protein. It is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With...
EflapegrastimA form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
Recombinant CD40-ligandRecombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
LeridistimLeridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).
FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
AvidinAvidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach).
LactoferrinLactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).
TengonerminTengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide....
GI-6207Not Annotated
EDI-200EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
HemopexinNot Annotated
Drugs & Drug Targets
DrugTargetType
PegfilgrastimGranulocyte colony-stimulating factor receptortarget
PegfilgrastimNeutrophil elastaseenzyme
FilgrastimGranulocyte colony-stimulating factor receptortarget
FilgrastimNeutrophil elastaseenzyme
OritavancinCytochrome P450 3A4enzyme
OritavancinCytochrome P450 2D6enzyme
OritavancinCytochrome P450 2C9enzyme
OritavancinCytochrome P450 2C19enzyme
OritavancinSerum albumincarrier
OritavancinPeptidoglycan precursorstarget
OritavancinBacterial cell wall peptide bridging segmentstarget
OritavancinPentaglycyl bridging segmenttarget
Human C1-esterase inhibitorComplement C1r subcomponenttarget
Human C1-esterase inhibitorComplement C1s subcomponenttarget
Human C1-esterase inhibitorPlasma kallikreintarget
Human C1-esterase inhibitorCoagulation factor XIItarget
Human C1-esterase inhibitorProthrombintarget
Human C1-esterase inhibitorCoagulation factor XItarget
Human C1-esterase inhibitorTissue-type plasminogen activatortarget
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
BleomycinDNA ligase 3target
BleomycinDNA ligase 1target
BleomycinDNAtarget
BleomycinBleomycin hydrolaseenzyme
VancomycinD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
VancomycinSerum albumincarrier
Vancomycinalpha1-acid glycoproteincarrier
VancomycinHistamine H1 receptorcarrier
TU-514UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylasetarget
PhosphoramidonNeprilysintarget
PhosphoramidonKell blood group glycoproteintarget
LJP 1082Beta-2-glycoprotein 1target
TeicoplaninD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
DalbavancinD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
NaxitamabGD2 disialogangliosidetarget
Simoctocog alfavon Willebrand factortarget
Darbepoetin alfaErythropoietin receptortarget
ErythropoietinErythropoietin receptortarget
SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
SargramostimBone marrow proteoglycantarget
SargramostimInterleukin-3 receptor subunit alphatarget
SargramostimCytokine receptor common subunit betatarget
SargramostimSyndecan-2target
Drotrecogin alfaCoagulation factor VIIItarget
Drotrecogin alfaCoagulation factor Vtarget
Drotrecogin alfaPlasminogen activator inhibitor 1target
Drotrecogin alfaThrombomodulintarget
Drotrecogin alfaVitamin K-dependent protein Starget
Drotrecogin alfaProthrombintarget
Drotrecogin alfaPlatelet factor 4target
Drotrecogin alfaPlasma serine protease inhibitortarget
Drotrecogin alfaSerpin B6target
Drotrecogin alfaEndothelial protein C receptortarget
Alpha-1-proteinase inhibitorNeutrophil elastasetarget
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
RomiplostimThrombopoietin receptortarget
RegramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
RegramostimGM-CSF receptor alpha subunittarget
RegramostimCholinesteraseenzyme
Thrombomodulin AlfaCoagulation factor Vtarget
Thrombomodulin AlfaProthrombintarget
PRO-542Free fatty acid receptor 4target
PegdinetanibVascular endothelial growth factor receptor 2target
ThrombopoietinThrombopoietin receptortarget
TG4010Mucin-1target
TG4010Interleukin-2target
Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
Conestat alfaComplement C1r subcomponenttarget
Conestat alfaComplement C1s subcomponenttarget
Conestat alfaPlasma kallikreintarget
Conestat alfaCoagulation factor XIItarget
Conestat alfaProthrombintarget
Conestat alfaCoagulation factor XItarget
Conestat alfaTissue-type plasminogen activatortarget
LenograstimGranulocyte colony-stimulating factor receptortarget
Protein S humanCoagulation factor Vtarget
Protein S humanCoagulation factor Xtarget
Protein S humanVitamin K-dependent protein Ctarget
LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
EflapegrastimGranulocyte colony-stimulating factor receptortarget